Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Top Cited Papers
Open Access
- 13 July 2006
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (2) , 125-137
- https://doi.org/10.1056/nejmoa062462
Abstract
The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established.Keywords
This publication has 28 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal WomenJAMA, 2002
- The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled TrialJournal of Clinical Endocrinology & Metabolism, 2000
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal WomenJAMA, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Molecular basis of agonism and antagonism in the oestrogen receptorNature, 1997
- Raloxifene is a Tissue‐Selective Agonist/Antagonist That Functions through the Estrogen ReceptorAnnals of the New York Academy of Sciences, 1995
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal WomenAnnals of Internal Medicine, 1992
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991